Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid

Clinical Infectious Diseases

Volumn 58, Issue 1, 2014, Pages 113-116

  Kabanda, Taseera ^a   Siedner, Mark J ^b   Klausner, Jeffrey D ^c   Muzoora, Conrad ^a   Boulware, David R ^d  

^a MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cryptococcal meningitis; diagnosis; HIV; point of care; sub Saharan Africa

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; INDIAN INK;

ARTICLE; ASSAY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCAL ANTIGEN LATERAL FLOW ASSAY; CRYPTOCOCCAL MENINGITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLASGOW COMA SCALE; HUMAN; LUMBAR PUNCTURE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

CRYPTOCOCCAL MENINGITIS; DIAGNOSIS; HIV; POINT-OF-CARE; SUB-SAHARAN AFRICA;

CEREBROSPINAL FLUID; COHORT STUDIES; CRYPTOCOCCUS; HUMANS; IMMUNOCHROMATOGRAPHY; MENINGITIS, CRYPTOCOCCAL; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY;

EID: 84891350644     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit641     Document Type: Article

References (19)

1. McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 2012; 7:e49541.
2. Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol 2013; 20:52-5.
3. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescent and children. Available at: www.who.int/hiv/pub/cryptococcal-disease 2011/en/. Accessed 22 March 2013.
4. Boulware DR, Meya D, Muzoora C, et al. ART initiation within the first 2 weeks of cryptococcal meningitis is associated with higher mortality: a multisite randomized trial. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 3-6 March 2013.
5. Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 2012; 64:76-81.
6. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
7. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-7.
8. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007; 11:iii, ix-51.
9. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009; 49:702-9.
10. Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource limited settings. J Acquir Immune Defic Syndr 2013; 63:e101-8.
11. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
12. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med 1974; 80:176-81.
13. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20:2183-91.
14. Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis 2009; 49:931-4.
15. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7:e1000384.
16. Brouwer AE, Teparrukkul P, Pinpraphaporn S, et al. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis 2005; 192:681-4.
17. Grinsell M, Weinhold LC, Cutler JE, Han Y, Kozel TR. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J Infect Dis 2001; 184:479-87.
18. Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDSrelated cryptococcal disease. HIV Clin Trials 2000; 1:1-6.
19. Antinori S, Radice A, Galimberti L, Magni C, Fasan M, Parravicini C. The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis. J Clin Microbiol 2005; 43: 5828-9.